Stocklytics Platform
Asset logo for symbol CARM
Carisma Therapeutics, Inc. - Common Stock
CARM49
$0.69arrow_drop_down11.39%-$0.08
Penny Stock
Asset logo for symbol CARM
CARM49

$0.69

arrow_drop_down11.39%

Performance History

Chart placeholder
Key Stats
Open$0.76
Prev. Close$0.78
EPS-1.52
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$27.35M
PE Ratio-
LOWHIGH
Day Range0.63
0.79
52 Week Range0.63
4.70
Ratios
EPS-1.52

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Carisma Therapeutics, Inc. - Common Stock (CARM)

Carisma Therapeutics, Inc. is a biotechnology company that focuses on the development of immunotherapies for the treatment of cancer. The company's lead product candidate, CT-0508, is a chimeric antigen receptor macrophage (CAR-M) therapy that harnesses the power of the immune system to fight against tumor cells. CAR-M therapy is a novel approach that combines the cell-killing ability of CAR-T cells with the phagocytic capacity of macrophages. This dual mechanism of action enables CT-0508 to target and destroy cancer cells more effectively than traditional therapies.
Carisma Therapeutics' innovative platform technology allows for the engineering of CAR-M cells that are capable of recognizing and eliminating a broad range of cancer cells. The company's proprietary CAR-M technology has shown promising results in preclinical studies and is now being evaluated in clinical trials. Carisma is also developing a pipeline of CAR-M products targeting different types of cancer, including solid tumors. The company's goal is to provide patients with safe and effective immunotherapies that can improve outcomes and potentially cure their cancer.
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Steven Kelly
Headquarters
Philadelphia
Employees
0
Exchange
NASDAQ
add Carisma Therapeutics, Inc. - Common Stock to watchlist

Keep an eye on Carisma Therapeutics, Inc. - Common Stock

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Carisma Therapeutics, Inc. - Common Stock's (CARM) price per share?

The current price per share for Carisma Therapeutics, Inc. - Common Stock (CARM) is $0.69. The stock has seen a price change of -$0.09 recently, indicating a -11.39% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Carisma Therapeutics, Inc. - Common Stock (CARM)?

For Carisma Therapeutics, Inc. - Common Stock (CARM), the 52-week high is $4.71, which is 579.51% from the current price. The 52-week low is $0.63, the current price is 9.43% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Carisma Therapeutics, Inc. - Common Stock (CARM) a growth stock?

Carisma Therapeutics, Inc. - Common Stock (CARM) has shown an average price growth of -2.59% over the past three years. It has received a score of -3 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Carisma Therapeutics, Inc. - Common Stock as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Carisma Therapeutics, Inc. - Common Stock (CARM) stock price performance year to date (YTD)?

As of the latest data, Carisma Therapeutics, Inc. - Common Stock (CARM) has a year-to-date price change of -75.61%. Over the past month, the stock has experienced a price change of -30.49%. Over the last three months, the change has been -31.42%. Over the past six months, the figure is -47.92%.
help

Is Carisma Therapeutics, Inc. - Common Stock (CARM) a profitable company?

Carisma Therapeutics, Inc. - Common Stock (CARM) has a net income of -$86.88M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -388.3% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $14.92M, with a revenue growth rate of 51.71%, providing insight into the company's sales performance and growth. Operating income is noted at -$88.73M. Furthermore, the EBITDA is -$63.37M.
help

What is the market capitalization of Carisma Therapeutics, Inc. - Common Stock (CARM)?

Carisma Therapeutics, Inc. - Common Stock (CARM) has a market capitalization of $27.36M. The average daily trading volume is 0.69, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level